Johnson & Johnson EVP exercises options and sells 21,721 shares

Rhea-AI Filing Summary

Johnson & Johnson (JNJ) insider trade: EVP, Innovative Medicine, R&D, John C. Reed exercised 21,721 employee stock options at $157.92 per share and sold 21,721 common shares at a weighted average price of $192.7072 on 10/17/2025. Following these transactions, he directly beneficially owned 10,658 common shares and held 43,442 derivative securities (options). The sale price reflects multiple trades between $192.69 and $192.87.

Insights

Equity governance analyst

Routine Form 4: option exercise and matched sale; neutral.

The EVP exercised employee stock options at an exercise price of $157.92 and sold an equivalent number of shares at a weighted average of $192.7072 on 10/17/2025. This aligns with standard liquidity and diversification behavior for executives.

The filing notes multiple sale executions between $192.69 and $192.87, and the options were granted under a long‑term incentive plan with three equal annual vesting installments. The derivative line shows 43,442 options remaining after these transactions.

As a routine insider transaction, this is typically not thesis‑changing. Subsequent filings may provide additional context on future exercises or holdings.

Insider Trade Summary

Net Seller: 21,721 shares ($4,185,793)

Net Sell 3 txns

Insider REED JOHN C

Role EVP, Innovative Medicine, R&D

Sold 21,721 shs ($4.19M)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Options (Right to Buy)	21,721	$157.92	$3.43M
Exercise	Common Stock	21,721	$157.92	$3.43M
Sale	Common Stock	21,721	$192.7072	$4.19M

Holdings After Transaction: Employee Stock Options (Right to Buy) — 43,442 shares (Direct); Common Stock — 32,379 shares (Direct)

Footnotes (1)

1. This transaction was executed in multiple trades at prices ranging from $192.69 to $192.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REED JOHN C

(Last) (First) (Middle)

ONE JOHNSON & JOHNSON PLAZA

(Street)

NEW BRUNSWICK NJ 08933

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
JOHNSON & JOHNSON [ JNJ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Innovative Medicine, R&D

3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/17/2025		M		21,721	A	$157.92	32,379	D
Common Stock	10/17/2025		S		21,721	D	$192.7072(1)	10,658	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Options (Right to Buy)	$157.92	10/17/2025		M			21,721	(2)	02/15/2034	Common Stock	21,721	$157.92	43,442	D

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $192.69 to $192.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

2. Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Laura H. McFalls, as attorney-in-fact for John C. Reed	10/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did JNJ executive John C. Reed report on Form 4?

He exercised 21,721 stock options at $157.92 and sold 21,721 shares at a weighted average of $192.7072 on 10/17/2025.

How many JNJ shares does the reporting person own after the transaction?

He beneficially owns 10,658 common shares directly after the reported transactions.

What derivative securities remain after the JNJ insider transaction?

He holds 43,442 employee stock options following the transactions.

What price range were the JNJ shares sold at on the trade date?

Sales were executed in multiple trades between $192.69 and $192.87; the weighted average sale price was $192.7072.

What is the vesting schedule for the exercised JNJ options?

The option award vests in three equal annual installments beginning on the first anniversary of the grant date.